NASDAQ:MEIP - MEI Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.46 +0.21 (+6.46 %)
(As of 05/20/2018 03:54 PM ET)
Previous Close$3.46
Today's Range$3.1510 - $3.55
52-Week Range$1.58 - $3.55
Volume1.04 million shs
Average Volume557,268 shs
Market Capitalization$129.14 million
P/E Ratio49.43
Dividend YieldN/A
Beta1.89

About MEI Pharma (NASDAQ:MEIP)

MEI Pharma logoMEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MEIP
CUSIPN/A
Phone858-369-7100

Debt

Debt-to-Equity RatioN/A
Current Ratio8.27
Quick Ratio8.27

Price-To-Earnings

Trailing P/E Ratio49.43
Forward P/E Ratio-3.89
P/E GrowthN/A

Sales & Book Value

Annual Sales$23.25 million
Price / Sales5.55
Cash Flow$0.0748 per share
Price / Cash46.27
Book Value$0.88 per share
Price / Book3.93

Profitability

EPS (Most Recent Fiscal Year)$0.07
Net Income$2.67 million
Net Margins-1,651.87%
Return on Equity-60.75%
Return on Assets-54.49%

Miscellaneous

Employees25
Outstanding Shares37,320,000

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma (NASDAQ:MEIP) announced its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.08. The firm earned $0.43 million during the quarter, compared to the consensus estimate of $0.40 million. MEI Pharma had a negative net margin of 1,651.87% and a negative return on equity of 60.75%. View MEI Pharma's Earnings History.

What price target have analysts set for MEIP?

3 analysts have issued 1 year price targets for MEI Pharma's shares. Their predictions range from $6.50 to $7.00. On average, they expect MEI Pharma's share price to reach $6.8333 in the next year. View Analyst Ratings for MEI Pharma.

What are Wall Street analysts saying about MEI Pharma stock?

Here are some recent quotes from research analysts about MEI Pharma stock:
  • 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (4/12/2018)
  • 2. Cann analysts commented, "MEI Pharma’s F2Q loss per share of $0.16 was higher than our estimated $0.09, due to operating expenses of $6.5 million, or 50.2% higher than our estimated $4.3 million. The higher than estimated expenses stemmed primarily from higher R&D expenses and costs associated with collaboration revenues. Higher R&D expenses are attributed to voruciclib expenses and increased R&D for ME-401. Our outlook for FY2019-23 revenue remains basically unchanged. Our FY2018 loss per share foreacast is being increased by 12% to account for higher anticipated R&D expense and costs associated with collaboration revenue." (2/8/2018)

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:
  • Dr. Daniel P. Gold Ph.D., Pres, CEO & Director (Age 64)
  • Mr. Brian G. Drazba CPA, Sec. & CFO (Age 57)
  • Mr. David M. Urso Esq., J.D., Sr. VP of Corp. Devel. and Gen. Counsel (Age 54)
  • Dr. Robert D. Mass M.D., Chief Medical Officer (Age 64)
  • David A. Walsey, VP of IR & Corp. Communications

Has MEI Pharma been receiving favorable news coverage?

News stories about MEIP stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEI Pharma earned a news sentiment score of 0.18 on Accern's scale. They also gave news headlines about the company an impact score of 45.27 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sio Capital Management LLC (2.50%), Russell Investments Group Ltd. (0.33%) and Algert Global LLC (0.27%). View Institutional Ownership Trends for MEI Pharma.

Which institutional investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for MEI Pharma.

Which institutional investors are buying MEI Pharma stock?

MEIP stock was purchased by a variety of institutional investors in the last quarter, including Sio Capital Management LLC. View Insider Buying and Selling for MEI Pharma.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $3.46.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $129.14 million and generates $23.25 million in revenue each year. The company earns $2.67 million in net income (profit) each year or $0.07 on an earnings per share basis. MEI Pharma employs 25 workers across the globe.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]


MarketBeat Community Rating for MEI Pharma (MEIP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MEI Pharma (NASDAQ:MEIP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for MEI Pharma in the last 12 months. Their average twelve-month price target is $6.8333, suggesting that the stock has a possible upside of 97.50%. The high price target for MEIP is $7.00 and the low price target for MEIP is $6.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.8333$6.8333$6.75$6.75
Price Target Upside: 97.50% upside250.43% upside200.00% upside193.48% upside

MEI Pharma (NASDAQ:MEIP) Consensus Price Target History

Price Target History for MEI Pharma (NASDAQ:MEIP)

MEI Pharma (NASDAQ:MEIP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018LaidlawInitiated CoverageBuy$7.00HighView Rating Details
3/21/2018CannReiterated RatingBuyMediumView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$7.00LowView Rating Details
8/2/2016WedbushReiterated RatingNeutral$2.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

MEI Pharma (NASDAQ:MEIP) Earnings History and Estimates Chart

Earnings by Quarter for MEI Pharma (NASDAQ:MEIP)

MEI Pharma (NASDAQ:MEIP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.13)($0.13)($0.13)
Q4 20181($0.10)($0.10)($0.10)
Q1 20191($0.08)($0.08)($0.08)
Q2 20191($0.10)($0.10)($0.10)

MEI Pharma (NASDAQ MEIP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q3 2018($0.2370)($0.16)$0.40 million$0.43 millionViewN/AView Earnings Details
2/8/2018Q2 2018($0.26)($0.16)$1.00 million$0.36 millionViewN/AView Earnings Details
11/8/2017Q1 2018($0.17)($0.24)$0.70 million$0.28 millionViewN/AView Earnings Details
9/5/2017Q4 2017($0.15)($0.12)$0.60 million$0.45 millionViewListenView Earnings Details
5/4/2017Q3 2017($0.0250)($0.02)$5.00 million$4.51 millionViewN/AView Earnings Details
2/8/2017Q217($0.29)$0.32$1.25 million$17.20 millionViewN/AView Earnings Details
11/8/2016Q1 2017($0.14)($0.12)$0.63 million$1.10 millionViewN/AView Earnings Details
9/6/2016Q4 2016($0.20)($0.17)ViewN/AView Earnings Details
5/5/2016Q3 2016($0.15)($0.16)ViewN/AView Earnings Details
2/5/2016Q2 2016($0.17)($0.15)ViewN/AView Earnings Details
11/6/2015Q1 2016($0.19)($0.13)ViewN/AView Earnings Details
9/2/2015Q4 2015($0.23)($0.17)ViewN/AView Earnings Details
5/7/2015Q3 2015($0.29)($0.27)ViewN/AView Earnings Details
9/9/2014Q4 2014($0.37)($0.40)ViewN/AView Earnings Details
5/8/2014Q3 2014($0.37)($0.34)ViewN/AView Earnings Details
2/11/2014Q2 2014($0.37)($0.32)ViewN/AView Earnings Details
11/8/2013Q1 2014($0.37)($0.29)ViewN/AView Earnings Details
9/18/2013Q4 2013($0.37)($0.19)ViewN/AView Earnings Details
5/9/2013Q3 2013($0.37)($0.18)ViewN/AView Earnings Details
2/12/2013Q2 2013($0.37)($0.50)ViewN/AView Earnings Details
11/13/2012Q1 2013($2.22)($4.20)ViewN/AView Earnings Details
9/18/2012Q4 2012($2.22)($4.26)ViewN/AView Earnings Details
5/15/2012Q3 2012($2.22)($5.58)ViewN/AView Earnings Details
2/9/2012Q2 2012($0.78)ViewN/AView Earnings Details
11/14/2011Q1 2012($1.46)ViewN/AView Earnings Details
9/29/2011Q4 2011($0.81)ViewN/AView Earnings Details
5/16/2011Q3 2011($1.06)ViewN/AView Earnings Details
9/1/2009Q4 2009($4.20)ViewN/AView Earnings Details
5/7/2008Q3 2008($3.60)($3.00)ViewN/AView Earnings Details
2/8/2008Q2 2008($3.60)($1.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MEI Pharma (NASDAQ:MEIP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MEI Pharma (NASDAQ MEIP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.25%
Institutional Ownership Percentage: 22.95%
Insider Trading History for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership by Quarter for MEI Pharma (NASDAQ:MEIP)

MEI Pharma (NASDAQ MEIP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2017Charles V Baltic IIIDirectorBuy11,000$2.25$24,750.0013,250View SEC Filing  
11/9/2015Vivo Ventures Vii, LlcMajor ShareholderSell390,572$1.84$718,652.48View SEC Filing  
1/21/2015Charles V Baltic IIIDirectorBuy5,000$3.81$19,050.00View SEC Filing  
12/9/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell79,085$6.01$475,300.85View SEC Filing  
12/8/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell9,004$6.05$54,474.20View SEC Filing  
6/30/2014Charles V Baltic IIIDirectorBuy2,000$6.56$13,120.00View SEC Filing  
10/29/2013Vivo Ventures Vii, LlcMajor ShareholderSell299,609$8.21$2,459,789.89View SEC Filing  
10/2/2013Vivo Ventures Vii, LlcMajor ShareholderSell581,646$10.16$5,909,523.36View SEC Filing  
8/16/2013Charles V Baltic IIIDirectorBuy2,600$6.82$17,732.00View SEC Filing  
6/28/2013Vivo Ventures Vii, LlcMajor ShareholderSell7,337$7.58$55,614.46View SEC Filing  
6/11/2013Vivo Ventures V, LlcMajor ShareholderSell13,727$7.80$107,070.60View SEC Filing  
5/16/2013Vivo Ventures Vii, LlcMajor ShareholderSell17,428$9.07$158,071.96View SEC Filing  
5/8/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell200,000$8.58$1,716,000.00View SEC Filing  
1/25/2013Charles V Baltic IIIDirectorBuy10,200$6.04$61,608.00View SEC Filing  
12/21/2012Charles V Baltic IIIDirectorBuy3,500$7.18$25,130.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MEI Pharma (NASDAQ MEIP) News Headlines

Source:
DateHeadline
Equities Analysts Set Expectations for MEI Pharmas Q4 2018 Earnings (MEIP)Equities Analysts Set Expectations for MEI Pharma's Q4 2018 Earnings (MEIP)
www.americanbankingnews.com - May 17 at 7:34 AM
MEI Pharma to Present Clinical Data at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingMEI Pharma to Present Clinical Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 16 at 5:31 PM
BRIEF-MEI Pharma Announces $75 Mln Private PlacementBRIEF-MEI Pharma Announces $75 Mln Private Placement
www.reuters.com - May 16 at 8:48 AM
MEI Pharma secures $75M capital raise; shares up 24%MEI Pharma secures $75M capital raise; shares up 24%
seekingalpha.com - May 15 at 3:21 PM
MEI Pharma (MEIP) Reports $75M Private Placement of Common Stock, WarrantsMEI Pharma (MEIP) Reports $75M Private Placement of Common Stock, Warrants
www.streetinsider.com - May 15 at 8:23 AM
MEI Pharma Announces $75 Million Private PlacementMEI Pharma Announces $75 Million Private Placement
finance.yahoo.com - May 14 at 9:42 AM
Oppenheimer Brokers Reduce Earnings Estimates for MEI Pharma (MEIP)Oppenheimer Brokers Reduce Earnings Estimates for MEI Pharma (MEIP)
www.americanbankingnews.com - May 14 at 3:33 AM
MEI Pharma (MEIP) Releases  Earnings ResultsMEI Pharma (MEIP) Releases Earnings Results
www.americanbankingnews.com - May 10 at 10:14 PM
MEI Pharma beats by $0.08, beats on revenueMEI Pharma beats by $0.08, beats on revenue
seekingalpha.com - May 9 at 5:25 PM
MEI Pharma Reports Third Quarter Fiscal Year 2018 ResultsMEI Pharma Reports Third Quarter Fiscal Year 2018 Results
finance.yahoo.com - May 9 at 5:25 PM
MEI Pharma (MEIP) Stock Rating Upgraded by ValuEngineMEI Pharma (MEIP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 12:10 AM
Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors - 2018 Pipeline Insights - ResearchAndMarkets.comPhosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors - 2018 Pipeline Insights - ResearchAndMarkets.com
www.businesswire.com - April 21 at 5:22 PM
MEI Pharma (MEIP) Stock Rating Upgraded by Zacks Investment ResearchMEI Pharma (MEIP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 4:17 PM
MEI Pharma (MEIP) Now Covered by LaidlawMEI Pharma (MEIP) Now Covered by Laidlaw
www.americanbankingnews.com - April 12 at 11:47 AM
MEI Pharma (MEIP) Downgraded by Zacks Investment Research to "Hold"MEI Pharma (MEIP) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 12 at 10:07 AM
MEI Pharma (MEIP) Upgraded to Buy by Zacks Investment ResearchMEI Pharma (MEIP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:58 AM
MEI Pharma (MEIP) Rating Lowered to Hold at Zacks Investment ResearchMEI Pharma (MEIP) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 1 at 1:34 PM
MEI Pharma (MEIP) PT Set at $7.00 by OppenheimerMEI Pharma (MEIP) PT Set at $7.00 by Oppenheimer
www.americanbankingnews.com - March 30 at 12:05 PM
MEI Pharma (MEIP) Downgraded by Zacks Investment ResearchMEI Pharma (MEIP) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 6:22 PM
MEI Pharma (MEIP) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowMEI Pharma (MEIP) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 5:20 PM
MEI Pharma (MEIP) Lifted to "Hold" at ValuEngineMEI Pharma (MEIP) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 11:21 AM
Cann Reiterates Buy Rating for MEI Pharma (MEIP)Cann Reiterates Buy Rating for MEI Pharma (MEIP)
www.americanbankingnews.com - March 21 at 4:40 PM
MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of DirectorsMEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors
finance.yahoo.com - February 26 at 8:48 AM
MEI Pharmas early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% - Seeking AlphaMEI Pharma's early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% - Seeking Alpha
seekingalpha.com - February 14 at 7:27 AM
MEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients ... - StreetInsider.comMEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients ... - StreetInsider.com
www.streetinsider.com - February 14 at 7:27 AM
MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast CancerMEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer
finance.yahoo.com - February 13 at 3:28 PM
MEI Pharma (MEIP) Rating Increased to Hold at Zacks Investment ResearchMEI Pharma (MEIP) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 10 at 7:24 AM
MEI Pharma Reports Second Quarter Fiscal Year 2018 Results - PR Newswire (press release)MEI Pharma Reports Second Quarter Fiscal Year 2018 Results - PR Newswire (press release)
www.prnewswire.com - February 9 at 7:16 AM
MEI Pharma Reports Second Quarter Fiscal Year 2018 ResultsMEI Pharma Reports Second Quarter Fiscal Year 2018 Results
finance.yahoo.com - February 8 at 3:28 PM
Cann Reaffirms Buy Rating for MEI Pharma (MEIP)Cann Reaffirms Buy Rating for MEI Pharma (MEIP)
www.americanbankingnews.com - February 8 at 2:38 PM
Head-To-Head Contrast: Gemphire Therapeutics (GEMP) versus MEI Pharma (MEIP)Head-To-Head Contrast: Gemphire Therapeutics (GEMP) versus MEI Pharma (MEIP)
www.americanbankingnews.com - January 28 at 9:14 PM
MEI Pharma (MEIP) versus Its Competitors Head to Head AnalysisMEI Pharma (MEIP) versus Its Competitors Head to Head Analysis
www.americanbankingnews.com - January 14 at 11:30 AM
ETF Preview: ETFs, Futures Strain to Recover from Weakness Sparked by Bond-Market Woes; Street Mulls Jobless Claims, PPI DataETF Preview: ETFs, Futures Strain to Recover from Weakness Sparked by Bond-Market Woes; Street Mulls Jobless Claims, PPI Data
www.nasdaq.com - January 11 at 9:33 AM
MEI Pharma (MEIP) Granted FDA Clearance of Investigational New Drug Application for CDK Inhibitor VoruciclibMEI Pharma (MEIP) Granted FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
www.streetinsider.com - January 8 at 5:42 PM
Critical Comparison: MEI Pharma (MEIP) & Its RivalsCritical Comparison: MEI Pharma (MEIP) & Its Rivals
www.americanbankingnews.com - January 3 at 11:30 PM
Head to Head Comparison: MEI Pharma (MEIP) & The CompetitionHead to Head Comparison: MEI Pharma (MEIP) & The Competition
www.americanbankingnews.com - January 1 at 7:28 AM
MEI Pharma (MEIP) vs. The Competition Critical ContrastMEI Pharma (MEIP) vs. The Competition Critical Contrast
www.americanbankingnews.com - December 29 at 7:24 PM
MEI Pharma (MEIP) versus The Competition Head-To-Head AnalysisMEI Pharma (MEIP) versus The Competition Head-To-Head Analysis
www.americanbankingnews.com - December 29 at 5:28 AM
ETFs with exposure to MEI Pharma, Inc. : December 25, 2017ETFs with exposure to MEI Pharma, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 3:30 PM
MEI Pharma (MEIP) Says Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports - StreetInsider.comMEI Pharma (MEIP) Says Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports - StreetInsider.com
www.streetinsider.com - December 23 at 6:05 AM
MEI Pharmas (MEIP) Buy Rating Reaffirmed at CannMEI Pharma's (MEIP) Buy Rating Reaffirmed at Cann
www.americanbankingnews.com - December 21 at 4:28 PM
MEI Pharma (MEIP) Given a $7.00 Price Target at OppenheimerMEI Pharma (MEIP) Given a $7.00 Price Target at Oppenheimer
www.americanbankingnews.com - December 21 at 4:28 PM
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific ReportsMEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
finance.yahoo.com - December 21 at 9:14 AM
ETFs with exposure to MEI Pharma, Inc. : December 12, 2017ETFs with exposure to MEI Pharma, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 6:01 PM
MEI Pharmas (MEIP) Buy Rating Reiterated at OppenheimerMEI Pharma's (MEIP) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 11 at 5:08 PM
MEI Pharma (MEIP) Receives "Buy" Rating from CannMEI Pharma (MEIP) Receives "Buy" Rating from Cann
www.americanbankingnews.com - December 11 at 9:00 AM
MEI Pharma (MEIP) Rating Lowered to Sell at ValuEngineMEI Pharma (MEIP) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 8:14 AM
MEI Pharma Inc (MEIP) Director Charles V. Baltic III Acquires 11,000 SharesMEI Pharma Inc (MEIP) Director Charles V. Baltic III Acquires 11,000 Shares
www.americanbankingnews.com - November 29 at 8:46 PM
Short Interest in MEI Pharma Inc (MEIP) Drops By 82.9%Short Interest in MEI Pharma Inc (MEIP) Drops By 82.9%
www.americanbankingnews.com - November 29 at 2:38 AM
MEI Pharma to Host Annual Meeting of StockholdersMEI Pharma to Host Annual Meeting of Stockholders
finance.yahoo.com - November 23 at 6:26 AM

SEC Filings

MEI Pharma (NASDAQ:MEIP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MEI Pharma (NASDAQ:MEIP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MEI Pharma (NASDAQ MEIP) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.